Leveraging AI to Address the Neuropsychiatric Conditions Associated with a Rare Disease
Neil Inala, CEO of Nobias Therapeutics, discusses how AI is transforming drug discovery, the data Nobias is able to use to fuel its drug discovery, and the company’s experimental therapy for the neuropsychiatric conditions associated with 22q11.2 deletion syndrome.